EnnovaBio key facts
- Manufacturer of innovative anti-cancer drugs based in Shanghai, China.
- It has raised $24.2M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Highlight Capital, Shanghai Healthcare Capital, Zhangjiang Group, Sailing Capital, KCH Capital Management Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch EnnovaBio: the Monday email on marks, rounds and moves
EnnovaBio funding rounds
No funding rounds for EnnovaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
EnnovaBio investors
10 investors are on record for EnnovaBio, including Highlight Capital, Shanghai Healthcare Capital, Zhangjiang Group and Sailing Capital.
About EnnovaBio
Manufacturer of innovative anti-cancer drugs based in Shanghai, China. The company specialises in targeted therapies, tumour immunotherapy candidates and proprietary platforms for overcoming drug resistance, thereby aiming to improve clinical outcomes and expand treatment options for patients with high medical needs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Website
- ennovabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
EnnovaBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.